Actualités Pharming Group NV - PHARM | Actions Euronext

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT...

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer Leiden, the Netherlands...

Pharming announces public cash offer to the shareholders of Abliva AB

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset...

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB Proposed acquisition strengthens Pharming’s late-stage pipeline with a...

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare...

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib Multinational Phase III study is evaluating leniolisib tablets...

Pharming Group to participate in November investor conference

Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:...

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group reports third quarter 2024 financial results and provides business update Third quarter 2024 total revenues increased by 12% to...

Pharming Group reports third quarter 2024 financial results and provides business update

Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023...

Pharming Group to report third quarter 2024 financial results on October 24

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:...

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V...

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of...

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered...

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric...

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

For media and investors only Indicated for adult and pediatric patients 12 years of age and older with...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

PHARM Actualités

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming Group to participate in November investor conference

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

PHARM Bilan

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM) Actualités

Pharming Group NV (PHARM)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

PHARM Actualités

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming Group to participate in November investor conference

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

PHARM Bilan

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités